RBC Capital analyst Gregory Renza downgraded Fusion Pharmaceuticals (FUSN) to Sector Perform from Outperform with a price target of $21, up from $16. The analyst believes the pending takeover by AstraZeneca (AZN) is likely to go through.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
- Fusion Pharmaceuticals to be acquired by AstraZeneca in $2.4B transaction
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer